Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
4D Molecular Therapeutics, Inc. (FDMT)
|
Add to portfolio |
|
|
|
| Price: |
$20.79
| | Metrics |
| OS: |
42.1
|
M
| |
|
|
| Market cap: |
$874
|
M
| |
|
|
|
Net cash:
|
$310
|
M
| |
$7.38
|
per share
|
|
EV:
|
$564
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
($124)
|
M
| |
|
|
| EPS |
($2.42)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-05-22 | Dec-31-21 | Dec-05-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 |
| Revenues | 3.1 | 3.1 | 18.0 | 18.0 | 13.4 | 7.0 | 14.1 | 5.8 |
| Revenue growth | -82.7% | -82.7% | 35.0% | | 91.3% | -50.6% | 144.0% | |
| Cost of goods sold | 0.0 | 113.2 | 0.0 | 89.4 | 0.0 | 0.0 | 0.0 | 17.1 |
| Gross profit | 3.1 | -110.0 | 18.0 | -71.3 | 13.4 | 7.0 | 14.1 | -11.3 |
| Gross margin | 100.0% | -3516.5% | 100.0% | -395.5% | 100.0% | 100.0% | 100.0% | -194.7% |
| Selling, general and administrative | 113.2 | | 89.4 | | 70.3 | | | |
| Research and development | 80.3 | | 61.4 | | 53.0 | 38.7 | | |
| General and administrative | | 32.9 | | 28.0 | | 13.9 | 6.2 | 3.5 |
| EBIT | -105.0 | -110.0 | -71.3 | -71.3 | -56.7 | -45.6 | -10.4 | -11.3 |
| EBIT margin | -3354.3% | -3516.5% | -395.3% | -395.5% | -424.5% | -653.1% | -73.6% | -194.7% |
| Pre-tax income | -107.5 | -107.5 | -71.3 | -71.3 | -56.7 | -49.3 | 0.0 | 0.0 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | | |
| Net income | -107.5 | -107.5 | -71.3 | -71.3 | -56.7 | -49.3 | 0.0 | 0.0 |
| Net margin | -3435.4% | -3435.4% | -395.4% | -395.4% | -424.3% | -705.8% | 0.0% | 0.0% |
| |
| Diluted EPS | ($3.32) | ($3.32) | ($2.57) | ($2.57) | ($8.82) | ($9.59) | $0.00 | $0.00 |
| Shares outstanding (diluted) | 32.4 | 32.4 | 27.7 | 27.7 | 6.4 | 5.1 | 5,049.2 | 4,953.4 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|